Bathla Group Hires Administrators as Australia Housing Slump Deepens 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Tesla Raises Cybertruck Prices by $5,000 in US 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Trump Buys SpaceX Shares After Record IPO 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Add as a preferred source on Google
TEL AVIV, Israel, May 01, 2018 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, May 17 at 8:30am Eastern Time to report first quarter ended March 31, 2018 financial results.
Thursday, May 17th @ 8:30am Eastern Time
US Domestic: 877-222-6394
International: 1-703-925-2702
Conference ID: 9993639
Webcast: https://edge.media-server.com/m6/p/zja7xger
Replays, Available through May 31, 2018
US Domestic: 855-859-2056
International: 1-404-537-3406
Conference ID: 9993639
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
